Hims & Hers Health (NYSE:HIMS) Stock Rating Lowered by Wall Street Zen

Hims & Hers Health (NYSE:HIMS) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday.

A number of other brokerages have also recently weighed in on HIMS. Bank of America boosted their price objective on Hims & Hers Health from $22.00 to $26.00 and gave the company an “underperform” rating in a research note on Tuesday, April 29th. Needham & Company LLC reissued a “hold” rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Piper Sandler reissued a “neutral” rating and issued a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. TD Cowen lowered Hims & Hers Health from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $44.00 to $30.00 in a report on Tuesday, April 29th. Finally, Truist Financial set a $45.00 price objective on Hims & Hers Health in a report on Tuesday, June 24th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and a consensus price target of $39.58.

Hims & Hers Health Stock Down 4.7%

HIMS stock opened at $47.91 on Friday. The business has a 50 day moving average price of $53.68 and a 200 day moving average price of $40.96. The stock has a market cap of $10.72 billion, a price-to-earnings ratio of 69.44, a PEG ratio of 1.85 and a beta of 2.02. Hims & Hers Health has a fifty-two week low of $13.47 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.08. The firm had revenue of $586.01 million during the quarter, compared to analysts’ expectations of $535.21 million. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The firm’s revenue was up 110.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.05 earnings per share. As a group, sell-side analysts anticipate that Hims & Hers Health will post 0.29 EPS for the current year.

Insider Buying and Selling

In other Hims & Hers Health news, insider Soleil Boughton sold 2,572 shares of the company’s stock in a transaction on Monday, June 30th. The stock was sold at an average price of $50.50, for a total value of $129,886.00. Following the sale, the insider owned 160,737 shares of the company’s stock, valued at approximately $8,117,218.50. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Oluyemi Okupe sold 11,581 shares of the company’s stock in a transaction on Monday, July 7th. The shares were sold at an average price of $46.67, for a total value of $540,485.27. Following the completion of the sale, the chief financial officer directly owned 58,078 shares in the company, valued at $2,710,500.26. This trade represents a 16.63% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 670,250 shares of company stock valued at $34,487,591 in the last three months. 13.71% of the stock is owned by insiders.

Institutional Trading of Hims & Hers Health

Several institutional investors and hedge funds have recently made changes to their positions in HIMS. Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health in the first quarter valued at $30,000. Summit Securities Group LLC purchased a new position in Hims & Hers Health during the fourth quarter worth about $38,000. UMB Bank n.a. boosted its stake in Hims & Hers Health by 247.5% in the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company’s stock worth $39,000 after buying an additional 933 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Hims & Hers Health in the 1st quarter worth about $41,000. Finally, Larson Financial Group LLC boosted its stake in Hims & Hers Health by 47.7% in the 1st quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock worth $42,000 after buying an additional 458 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.